Now showing items 1-4 of 4

    • Assessing HER2 Amplification in Plasma cfDNA. 

      Garcia-Murillas, I; Turner, NC (2018-01)
      Digital PCR (dPCR) is a highly accurate method to determine DNA concentration. In dPCR, DNA is portioned into many discrete single entities, and these are analyzed individually for the presence or absence of a target ...
    • High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. 

      Pearson, A; Smyth, E; Babina, IS; Herrera-Abreu, MT; Tarazona, N; Peckitt, C; Kilgour, E; Smith, NR; Geh, C; Rooney, C; Cutts, R; Campbell, J; Ning, J; Fenwick, K; Swain, A; Brown, G; Chua, S; Thomas, A; Johnston, SRD; Ajaz, M; Sumpter, K; Gillbanks, A; Watkins, D; Chau, I; Popat, S; Cunningham, D; Turner, NC (2016-08)
      <h4>Unlabelled</h4>FGFR1 and FGFR2 are amplified in many tumor types, yet what determines response to FGFR inhibition in amplified cancers is unknown. In a translational clinical trial, we show that gastric cancers with ...
    • Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. 

      Ng, CKY; Martelotto, LG; Gauthier, A; Wen, H-C; Piscuoglio, S; Lim, RS; Cowell, CF; Wilkerson, PM; Wai, P; Rodrigues, DN; Arnould, L; Geyer, FC; Bromberg, SE; Lacroix-Triki, M; Penault-Llorca, F; Giard, S; Sastre-Garau, X; Natrajan, R; Norton, L; Cottu, PH; Weigelt, B; Vincent-Salomon, A; Reis-Filho, JS (2015-05-22)
      <h4>Background</h4>HER2 is overexpressed and amplified in approximately 15% of invasive breast cancers, and is the molecular target and predictive marker of response to anti-HER2 agents. In a subset of these cases, ...
    • Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney. 

      Little, SE; Bax, DA; Rodriguez-Pinilla, M; Natrajan, R; Messahel, B; Pritchard-Jones, K; Vujanic, GM; Reis-Filho, JS; Jones, C (2007-08)
      <h4>Purpose</h4>Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase overexpressed in a variety of human malignancies, against which targeted therapies have shown efficacy in lung and brain tumors. Clinical ...